CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 

Vir Biotechnology Inc 's Leverage Ratio

VIR's quarterly Leverage Ratio and Total Liabilities, Equity growth




VIR Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change 145.34 % 164.74 % 207.4 % 99.74 % 7.87 %
Y / Y Total Liabilities Change 108.38 % 108.95 % 77.18 % 180.41 % 126.9 %
Leverage Ratio MRQ 0.25 0.27 0.37 0.26 0.3
Overall Ranking # 656 # 764 # 1029 # 905 # 1039
Seq. Equity Change 10.14 % -2.45 % 39.75 % 63.4 % 18.85 %
Seq. Total Liabilities Change 5.36 % -29.46 % 98.39 % 41.34 % 5.65 %



Leverage Ratio third quarter 2022 Comment
In Spite of the net new borrowings of 5.36% Vir Biotechnology Inc managed to improve Leverage Ratio in the third quarter 2022 to 0.25, below company's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2022, 75 other companies have achieved lower Leverage Ratio than Vir Biotechnology Inc . While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are VIR Customers?
Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 76
Healthcare Sector # 334
Overall Market # 656


Leverage Ratio Statistics
High Average Low
0.64 0.28 0.14
(Mar 31 2021)   (Sep 30 2020)




Financial Statements
Vir Biotechnology Inc 's Equity $ 2,150 Millions Visit VIR's Balance sheet
Vir Biotechnology Inc 's Total Liabilities $ 546 Millions Visit VIR's Balance sheet
Source of VIR's Sales Visit VIR's Sales by Geography


Cumulative Vir Biotechnology Inc 's Leverage Ratio

VIR's Leverage Ratio for the trailling 12 Months

VIR Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth 145.34 % 164.74 % 207.4 % 99.74 % 7.87 %
Y / Y Total Liabilities TTM Growth 108.38 % 108.95 % 77.18 % 180.41 % 126.9 %
Leverage Ratio TTM 0.29 0.3 0.32 0.35 0.35
Total Ranking TTM # 785 # 918 # 545 # 1073 # 895
Seq. Equity TTM Growth 10.14 % -2.45 % 39.75 % 63.4 % 18.85 %
Seq. Total Liabilities TTM Growth 5.36 % -29.46 % 98.39 % 41.34 % 5.65 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Despite of the net new borrowings of 5.36% Vir Biotechnology Inc managed to decrease Leverage Ratio in III. Quarter to 0.29, below Vir Biotechnology Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 101 other companies have achieved lower Leverage Ratio than Vir Biotechnology Inc . While Leverage Ratio total ranking has improved so far to 785, from total ranking in previous quarter at 918.

Explain Leverage Ratio?
Who are VIR Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 102
Healthcare Sector # 405
Within the Market # 785


TTM Leverage Ratio Statistics
High Average Low
1.03 0.47 0.19
(Mar 31 2020)   (Sep 30 2020)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Equity
Seqll Inc   0.70 $ 3.837  Millions$ 5.513  Millions
Conformis inc   0.68 $ 41.509  Millions$ 61.165  Millions
Lineage Cell Therapeutics Inc   0.67 $ 52.200  Millions$ 77.553  Millions
Elevation Oncology inc   0.66 $ 44.371  Millions$ 67.121  Millions
Telesis Bio Inc   0.65 $ 34.834  Millions$ 53.308  Millions
Chase Corporation  0.64 $ 238.751  Millions$ 372.829  Millions
Natural Health Trends Corp   0.63 $ 32.686  Millions$ 51.909  Millions
Candel Therapeutics Inc   0.62 $ 32.428  Millions$ 52.127  Millions
Poseida Therapeutics Inc   0.62 $ 134.387  Millions$ 216.313  Millions
Nanovibronix Inc  0.61 $ 1.909  Millions$ 3.154  Millions
Align Technology inc   0.60 $ 2,218.180  Millions$ 3,694.622  Millions
Sana Biotechnology Inc   0.59 $ 332.083  Millions$ 566.019  Millions
Recursion Pharmaceuticals Inc   0.58 $ 223.499  Millions$ 388.034  Millions
Eyepoint Pharmaceuticals Inc   0.57 $ 77.905  Millions$ 136.350  Millions
Cel sci Corporation  0.57 $ 18.360  Millions$ 32.163  Millions
Regenxbio Inc   0.57 $ 319.969  Millions$ 563.824  Millions
Hydrofarm Holdings Group Inc   0.56 $ 214.769  Millions$ 382.505  Millions
Finch Therapeutics Group Inc   0.56 $ 67.102  Millions$ 120.866  Millions
Century Therapeutics inc   0.55 $ 181.546  Millions$ 330.205  Millions
Myomo Inc   0.53 $ 4.114  Millions$ 7.822  Millions
Bluebird Bio Inc   0.52 $ 83.028  Millions$ 158.857  Millions
Denali Therapeutics Inc   0.51 $ 416.303  Millions$ 811.303  Millions
Kodiak Sciences Inc   0.51 $ 244.459  Millions$ 479.529  Millions
Gritstone Bio Inc   0.50 $ 68.395  Millions$ 136.847  Millions
Berkeley Lights Inc   0.48 $ 76.701  Millions$ 158.183  Millions
Voyager Therapeutics Inc   0.48 $ 38.636  Millions$ 79.823  Millions
Immucell Corp  0.45 $ 14.419  Millions$ 31.983  Millions
C4 Therapeutics Inc   0.45 $ 143.260  Millions$ 318.179  Millions
Moderna Inc   0.45 $ 8,064.000  Millions$ 17,992.000  Millions
Vaxart Inc   0.43 $ 53.002  Millions$ 122.307  Millions

Date modified: 2022-11-06T04:16:49+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

VCOR's Profile

Stock Price

VCOR's Financials

Business Description

Fundamentals

Charts & Quotes

VCOR's News

Suppliers

VCOR's Competitors

Customers & Markets

Economic Indicators

VCOR's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071